v3.24.1.1.u2
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Federal grants $ 305,722 $ 789,635
Operating expenses:    
Research and development 778,904 1,796,015
General and administrative 1,369,782 1,554,855
Total operating expenses 2,148,686 3,350,870
Loss from operations (1,842,964) (2,561,235)
Other income (expense):    
Change in fair value of convertible notes 146,479
Change in fair value of liability classified warrants 8,955 219,028
Interest expense, net (1,248,065) (1,497)
Other income and expense, net (34,489) 5,419
Total other income, net (1,273,599) 369,429
Net loss (3,116,563) (2,191,806)
Net loss attributable to noncontrolling interests (74) (3,941)
Deemed dividend related to warrants down round provision 290 8,309
Net loss attributable to common stockholders $ (3,116,779) $ (2,196,174)
Net loss per basic and diluted share:    
Net loss per share attributable to common stockholders, basic $ (0.55) $ (2.08)
Net loss per share attributable to common stockholders, diluted $ (0.55) $ (2.08)
Weighted average common shares outstanding, basic 5,694,466 1,054,202
Weighted average common shares outstanding, diluted 5,694,466 1,054,202

Source